Page 13 - Biocon

Biocon Biologics to go for IPO in 18-24 months: Kiran Mazumdar-Shaw

Biocon arm buys Viatris biosimilars biz for $3.2 billion

Biocon beefs up biosimilar portfolio with $3.3-bn Viatris deal, shares fall

The company in a statement said that its subsidiary Biocon Biologics has inked a pact to acquire Viatris Inc's biosimilars business for consideration of up to USD 3.335 billion

Sensex ends 1,414 pts off low, gains 389 pts; Tata Steel rises 6%, RIL 3%

Closing Bell: Hindalco (up over 7 per cent), Tata Steel, Power Grid, JSW Steel, Coal India, BPCL, Titan Company, RIL, and Indian Oil Corporation were the biggest large-cap gainers on the bourses today

Biocon arm plans to acquire Viatris' biosimilars assets; stock falls 8%

The companies will also enter into a transition services agreement. Viatris will provide certain transition services, including commercialization services for an expected 2-years

Biocon Biologics acquires Viatris' biosimilars business in $3.3 bn deal

BBL will also obtain Viatris' rights in all biosimilars assets, including its in-licensed portfolio and an option to acquire Viatris' rights in bAflibercept

Rahul Bajaj: Mahindra, Mazumdar-Shaw among industry leaders to pay tribute

Industry leaders on Saturday paid rich tributes to noted industrialist Rahul Bajaj (83) who passed away due to illness at his home in Pune. Taking to Twitter, Mahindra Group Chairman Anand Mahindra stated: I stand on the shoulders of giants. Thank you, Rahulbhai, for letting me clamber up onto your broad shoulders, advising me, cheering me on, encouraging me to be bold. Your footprints on the sands of Indian Business will never be extinguished." Biocon Executive Chairperson Kiran Mazumdar-Shaw tweeted: "Industrialist Rahul Bajaj, Former Chairman Of Bajaj Group, Dies At 83 - I am devastated - he was a dear dear friend and will miss him dearly. The country has lost a great son & nation builder." TVS Motor Company Chairman Venu Srinivasan stated that Bajaj strode across the Indian industrial landscape like a colossus. "He was among the few stars who created the Indian automotive industry. He was a pioneer who established a culture of quality and technology. He stood for high ...

Biocon gains 3%, at 6-month high in a weak market; stock up 18% in 3 weeks

Biocon said its subsidiary Biocon Pharma has received approval of its ANDA for Posaconazole Delayed-Release tablets from the US FDA.

R&D expenditure will rise in the coming quarters: Biocon Biologics MD

In a Q&A, Dr Arun Chandavarkar spoke on how its interchangeable insulin biosimilar has driven the business

Biocon rises over 3% as biotech major sees strong Dec qtr numbers

Notwithstanding the muted broader market trend, shares of Biocon Ltd surged over 3 per cent on Friday after the biotechnology major reported strong December quarter earnings. On BSE, the stock opened at Rs 363, then touched a high of Rs 382.45, registering a gain of 5.09 per cent over its last close. The stock finally ended at Rs 376.60, up 3.49 per cent. In a similar trend on NSE, the stock opened at Rs 364.00, then jumped 5.02 per cent and touched an early high of Rs 382.50 in initial deals. It finally settled at Rs 376.45, up 3.36 per cent. On Thursday, biotechnology major Biocon Ltd reported a 17.68 per cent rise in consolidated net profit at Rs 219.6 crore for the third quarter ended December 31, 2021. The company had posted a consolidated net profit of Rs 186.6 crore in the same quarter of the previous fiscal. Consolidated total income in the third quarter this fiscal stood at Rs 2,222.5 crore, compared to Rs 1,885.3 crore a year ago. The biosimilars vertical clocked revenue

Stocks to Watch: RIL, Asian Paints, HUL, BoM, PNB Housing, VodaIdea, Biocon

Bandhan Bank, HDFC Life, Hindustan Zinc, Voda Idea, Inox Leisure, JSW Steel, Kajaria Ceramics, L&T Fin Holdings, PVR, Reliance Industries, SBI Life and Supriya Lifescience to announce results today

Biocon consolidated net profit rises 18% to Rs 220 crore in Q3

Biosimilars vertical clocked revenue of Rs 981.4 crore as compared to Rs 768.9 crore in the same quarter last fiscal

Sensex falls for 3rd straight day, sheds 634 pts; Nifty holds 17,750

Analysts, however, expect markets to recover from here on as they have reached their key support zones.

USFDA rejects Biocon, Viatris application for Insulin Aspart

The company will respond to the CRL to satisfy the FDA's requests

Biocon Biologics partner Viatris wins favourable order from US court

Biocon Biologics Ltd, said its partner Viatris has won favourable decisions from a US federal court in Sanofi's challenge over unpatentability of device patents for disposable insulin injection pen

Trials start for Equillium drug for autoimmune disease after India approval

Equillium secured exclusive rights to develop and commercialise itolizumab for the US and Canada markets, in May 2017.

Trading strategies for Bandhan Bank & Ambuja Cement by Ajit Mishra

The stock of Bandhan Bank has been underperforming the banking index and is still struggling below the resistance zone of moving averages

Biocon in talks with Mylan to merge biosimilar businesses: Report

Indian drugmaker Biocon Ltd is in talks with generic drugmaker Mylan for a merger of their biosimilar businesses, a report said

Biocon ties up with Tabuk Pharmaceuticals to sell medicines in Middle East

Biocon said it has inked a pact with Saudi Arabia-based drug firm Tabuk Pharmaceutical Manufacturing Company to commercialise select speciality products in Middle East region

Biotechnology major Biocon gets USFDA approval for generic product

The product is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant

Biocon enters Dow Jones Sustainability Index in Emerging Markets category

Pharma major makes it to the DJSI EM Index with a total sustainability score of 45 as against an industry average of 18